Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)

BACKGROUND: The FAST is a 2 × 2 factorial trial addressing two questions: (1) the role of replacing cisplatin (P) with a non-platinum agent, vinorelbine (N), and (2) the role of adding a third agent, ifosfamide (I), in a doublet based on gemcitabine (G). METHODS: A total of 433 stage IIIB–IV non-sma...

Descripción completa

Detalles Bibliográficos
Autores principales: Boni, C, Tiseo, M, Boni, L, Baldini, E, Recchia, F, Barone, C, Grossi, F, Germano, D, Matano, E, Marini, G, Labianca, R, Di Costanzo, F, Bagnulo, A, Pennucci, C, Caroti, C, Mencoboni, M, Zanelli, F, Prochilo, T, Cafferata, M A, Ardizzoni, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322957/
https://www.ncbi.nlm.nih.gov/pubmed/22240782
http://dx.doi.org/10.1038/bjc.2011.606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322957/
https://www.ncbi.nlm.nih.gov/pubmed/22240782
http://dx.doi.org/10.1038/bjc.2011.606

Ejemplares similares